Karyopharm Therapeutics | KPTI - Operating Expenses


Karyopharm Therapeutics reported $51.92M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Abbott USD 10.46B 1.15B Jun/2026
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
J&J USD 17.83B 388M Jun/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
MacroGenics USD 21.2M 32.13M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novartis USD 9.29B 507M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Takeda JPY 1.11T 85.29B Mar/2026
Tectonic Therapeutic USD 27.3M 5.78M Mar/2026
TG Therapeutics USD 170.12M 28.04M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Xencor USD 82.38M 513K Mar/2026